By Rush PT
If you and your clinician have agreed that GLP-1 treatment will end, make a separate plan for your exercise support. Agree who will help you keep training, what happens to any supervised sessions and when you’ll review how things are going. Evidence from treatment follow-ups makes those questions worth asking.
Your usual clinician remains responsible for medication decisions. The practical coaching task is to make sure a change in treatment doesn’t leave your training arrangements hanging. There’s enough administration in life without your exercise plan disappearing into the paperwork.
What the exercise follow-up actually studied
The S-LiTE follow-up published in 2024 is often mentioned in this conversation. The original trial enrolled adults aged 18–65 with obesity, without diabetes. After an initial diet-induced weight loss, 195 people were allocated to a year of supervised exercise, liraglutide, both, or placebo. Both study medication and supervised exercise support then ended.
Only 109 people attended the assessment a year later. Results suggested advantages associated with having previously received exercise, but important comparisons were uncertain. For example, the combined group’s estimated 5.1 kg weight advantage over the liraglutide-only group did not meet the study’s statistical threshold after allowing for multiple comparisons.
The study followed people after an earlier randomised intervention. It didn’t test starting a new workout programme when medication stopped, and participants weren’t randomly assigned to their exercise habits during the follow-up year. It offers a reason to take ongoing activity support seriously, with substantial uncertainty about individual results.
A withdrawal trial answers a different question
Withdrawal studies also show why exercise planning belongs alongside medical follow-up. In SURMOUNT-4, 670 adults with obesity or overweight and a weight-related complication, without diabetes, were randomised after 36 weeks of tirzepatide treatment. Over the next 52 weeks, the group switched to placebo gained an average 14% of their week-36 body weight. Those continuing treatment lost a further 5.5% on average. Both groups received lifestyle counselling.
Those are group averages from a particular withdrawal trial. They can’t predict what will happen to you, or tell your clinician whether to continue, switch or otherwise adjust treatment. Bring changes in appetite, symptoms and day-to-day function into the review. A change in weight deserves a conversation, without turning it into a verdict on your effort.
Check what support will actually continue
Before the treatment review, list the exercise support you currently use. This might include a supervised session, a written programme, a check-in or help choosing suitable activities. Ask which arrangements will continue and whether any need a new booking or referral. A treatment appointment and a training appointment may have different end dates.
This is a practical handover, rather than a workout tested in a withdrawal trial. Write down the activity you can currently manage, who helps you adapt it and the next time you’ll speak. If you’re leaving a structured programme, ask for the relevant exercise guidance to take with you.
The 2026 ACSM resistance-training guidance supports regular participation and individualising training to goals and ability. It summarises healthy-adult research, so it provides general direction for strength work. It doesn’t establish a specific exercise prescription for the period after medication ends.
Keep a suitable mix of strength and aerobic activity in the handover discussion. The aim is to carry forward an appropriate routine with enough support to adjust it. Ask about an agreed alternative if your usual class, equipment or supervision becomes unavailable. “I’ll work it out later” is an impressively flexible plan, right up until later arrives.
Make the handover useful
At your treatment review, ask what you should monitor, which symptoms need prompt advice and when the next review should happen. Ask who to contact if appetite, eating or recovery becomes difficult. Let your coach know about relevant exercise guidance from the treating team.
A supportive-care consensus for GLP-1-based treatment brings nutrition, activity and continuing support into the same discussion. It was developed through a structured expert-consensus process, drawing on evidence and clinical experience. It supplies guidance rather than a trial proving one exercise routine works for everyone.
A coach can help organise sessions and adapt the training tasks. Questions about medication and persistent symptoms belong with the treating clinician, while an accredited practising dietitian can help with nutrition needs. If you’re unwell or struggling to keep fluids down, seek medical advice before a demanding workout.
Leave with a short, usable handover
You could keep the agreed details in a note on your phone. Include your current suitable activities, the support that will continue, the next review date and the person to contact if you can’t manage the plan. Ask the clinician what changes should bring that review forward.
At the follow-up, describe what you actually managed and any difficulty with familiar exercises or everyday activities. Take any measurements the treating team requested. That gives everyone something concrete to discuss when deciding whether the support or training needs adjusting.
Our guide to GLP-1 treatment, strength and fitness explains the wider exercise evidence. If you’d like help organising an adaptable training routine, contact Rush PT about personal training in Sydney’s Eastern Suburbs or online coaching. Bring your current goals and any relevant guidance from your treating team.